Alex Guminski

4.3k total citations
35 papers, 1.1k citations indexed

About

Alex Guminski is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alex Guminski has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alex Guminski's work include Cancer Immunotherapy and Biomarkers (12 papers), Melanoma and MAPK Pathways (10 papers) and CAR-T cell therapy research (7 papers). Alex Guminski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Melanoma and MAPK Pathways (10 papers) and CAR-T cell therapy research (7 papers). Alex Guminski collaborates with scholars based in Australia, United States and Germany. Alex Guminski's co-authors include Georgina V. Long, Alexander M. Menzies, Richard Kefford, Matteo S. Carlino, Serigne Lo, Richard A. Scolyer, Helen Rizos, Jenny Lee, Graham J. Mann and Stephanie Boyd and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

Alex Guminski

33 papers receiving 1.1k citations

Peers

Alex Guminski

ONCOL

PRM

OTORH

Édith Borcoman France

Youling Gong China

Charles Schneider United States

Christine Ciunci United States

Roshal R. Patel United States

Tomasz Rutkowski Poland

Miriam Hatsue Honda Federico Brazil

Mayra Ramos Cuba

Jinbo Yue China

Chi‐Leung Chiang Hong Kong

Édith Borcoman France

Alex Guminski

948 ×1.3

ONCOL

419 ×0.9

PRM

239 ×0.9

69 ×0.3

OTORH

170 ×0.8

Citations per year, relative to Alex Guminski Alex Guminski (= 1×) peers Édith Borcoman

Countries citing papers authored by Alex Guminski

Since Specialization

Citations

This map shows the geographic impact of Alex Guminski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Guminski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Guminski more than expected).

Fields of papers citing papers by Alex Guminski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Guminski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Guminski. The network helps show where Alex Guminski may publish in the future.

Co-authorship network of co-authors of Alex Guminski

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Guminski. A scholar is included among the top collaborators of Alex Guminski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Guminski. Alex Guminski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Azad, Arun, Mathias Bressel, Hsiang Tan, et al.. (2024). LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 35. S1255–S1256. 1 indexed citations

Grob, Jean‐Jacques, Caroline Gaudy‐Marqueste, Alex Guminski, et al.. (2021). Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. Journal of the European Academy of Dermatology and Venereology. 35(11). 2149–2153. 22 indexed citations

Oh, Byeongsang, Frances Boyle, Nick Pavlakis, et al.. (2021). Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. Frontiers in Oncology. 11. 706331–706331. 32 indexed citations

Migden, Michael R., Danny Rischin, Stacie Hudgens, et al.. (2020). 1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial. Annals of Oncology. 31. S738–S738. 1 indexed citations

Dummer, Reinhard, et al.. (2020). Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. Journal of the American Academy of Dermatology. 84(4). 1162–1164. 11 indexed citations

Guminski, Alex, et al.. (2019). Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Reports. 5(6). 491–494. 13 indexed citations

Emmett, Louise, Megan Crumbaker, Bao Ho, et al.. (2018). Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clinical Genitourinary Cancer. 17(1). 15–22. 126 indexed citations

Sanders, Peter, et al.. (2018). Tu1243 - Checkpoint Inhibitor Immunotherapy Side-Effects in GI Practice. Gastroenterology. 154(6). S–912. 1 indexed citations

Lee, Jenny, Georgina V. Long, Stephanie Boyd, et al.. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology. 28(5). 1130–1136. 232 indexed citations

10.

Menzies, Alexander M., Maria Gonzalez, Alex Guminski, et al.. (2017). Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma. Annals of Oncology. 28. v432–v432. 29 indexed citations

11.

Maio, Michele, Lev Demidov, Mario Mandalà, et al.. (2017). BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence. Annals of Oncology. 28. v631–v632. 6 indexed citations

12.

Parakh, Sagun, John Park, Shehara Mendis, et al.. (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer. 116(12). 1558–1563. 81 indexed citations

13.

Charles, Kellie A., Benjamin Harris, Carol Haddad, et al.. (2016). Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients. BMC Cancer. 16(1). 124–124. 55 indexed citations

14.

Carlino, Matteo S., Vito Vanella, Diana Giannarelli, et al.. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. British Journal of Cancer. 115(11). 1280–1284. 22 indexed citations

15.

Kong, Benjamin Y., Alexander M. Menzies, Catherine A.B. Saunders, et al.. (2016). Residual FDG‐PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐PD‐1 therapy. Pigment Cell & Melanoma Research. 29(5). 572–577. 67 indexed citations

16.

Ahn, Myung‐Ju, Anil D′Cruz, Jan B. Vermorken, et al.. (2015). Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology. 53. 10–16. 82 indexed citations

17.

Wargo, Jennifer A., Rodabe N. Amaria, Merrick I. Ross, et al.. (2015). Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.. Journal of Clinical Oncology. 33(15_suppl). TPS9091–TPS9091. 3 indexed citations

18.

Dummer, Reinhard, Alex Guminski, Ralf Gutzmer, et al.. (2014). Randomized, Double-Blind Study of Sonidegib (Lde225) in Patients (Pts) with Advanced Basal Cell Carcinoma (Bcc). Annals of Oncology. 25. v1–v1. 2 indexed citations

19.

Pryor, David, Sandro Porceddu, Bryan Burmeister, et al.. (2008). Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiotherapy and Oncology. 90(2). 172–176. 89 indexed citations

20.

Saunders, Nicholas A., William B. Coman, & Alex Guminski. (2007). Cancer of the head and neck. Queensland's institutional digital repository (The University of Queensland). 1–26. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact